The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
RetractedAngiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Self-citationTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441
The role of angiogenesis in tumor growth.
Folkman, J. (1992) · PubMed · Cited by 1,259
FUNCTION AND REGULATION OF RAS
Lowy, D. R., & Willumsen, B. M. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.004223 · Cited by 1,186
Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB
Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., & Evan, G. (1997) · Nature · doi:10.1038/385544a0 · Cited by 1,148
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Takahashi, H., & Shibuya, M. (2005) · Clinical Science · doi:10.1042/cs20040370 · Cited by 953
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872
Molecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
VDAC2 Inhibits BAK Activation and Mitochondrial Apoptosis
Cheng, E. H.-Y., Sheiko, T. V., Fisher, J. K., Craigen, W. J., & Korsmeyer, S. J. (2003) · Science · doi:10.1126/science.1083995 · Cited by 852
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809
Antonsson, B., & Martinou, J.-C. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4839 · Cited by 792
Cellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781
McGill, G. G., Horstmann, M., Widlund, H. R., Du, J., Motyckova, G., Nishimura, E. K., Lin, Y.-L., Ramaswamy, S., Avery, W., Ding, H.-F., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00762-6 · Cited by 760
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions
Borner, C. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(02)00252-3 · Cited by 703
Sporn, M. B. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91015-6 · Cited by 692
FERRARA, N. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70064-x · Cited by 623
Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A.-P., Noel, S., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602258 · Cited by 605
Issues and progress with protein kinase inhibitors for cancer treatment
Dancey, J., & Sausville, E. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1066 · Cited by 526
The ins and outs of Raf kinases
Daum, G., Eisenmann-Tappe, I., Fries, H.-W., Troppmair, J., & Rapp, U. R. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90133-3 · Cited by 524
Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 488
Pietras, K., & Hanahan, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
Ciampi, R., Knauf, J. A., Kerler, R., Gandhi, M., Zhu, Z., Nikiforova, M. N., Rabes, H. M., Fagin, J. A., & Nikiforov, Y. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523237 · Cited by 461
Smith, K., Gunaratnam, L., Morley, M., Franovic, A., Mekhail, K., & Lee, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0169 · Cited by 458
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457
Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer?
Welch, H. G. (2000) · JAMA · doi:10.1001/jama.283.22.2975 · Cited by 449
Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Belle, P. A. V., Elder, D. E., & Herlyn, M. (2003) · PubMed · Cited by 445
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426
Du, J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., Ross, K., Huber, W. E., Nishimura, E. K., Golub, T. R., & Fisher, D. E. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.014 · Cited by 421
Rini, B. I., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.186 · Cited by 408
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 408
Rusch, V. W., Klimstra, D. S., Venkatraman, E. S., Pisters, P. W. T., Langenfeld, J. E., & Dmitrovsky, E. (1997) · PubMed · Cited by 401
Bouillet, P., & Strasser, A. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.8.1567 · Cited by 379
高橋, 敦. (1994) · Medical Entomology and Zoology · doi:10.11501/3101325 · Cited by 352
Escudier, B., Szczylik, C., Eisen, T., Stadler, W. M., Schwartz, B., Shan, M., & Bukowski, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba4510 · Cited by 348
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing
Domingo, E., Laiho, P., Ollikainen, M., Pinto, M., Wang, L., French, A. J., Westra, J., Frebourg, T., Espín, E., Armengol, M., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.020651 · Cited by 339
Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli
Alavi, A., Hood, J. D., Frausto, R., Stupack, D. G., & Cheresh, D. A. (2003) · Science · doi:10.1126/science.1082015 · Cited by 336
Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1
O'Neill, E., Rushworth, L., Baccarini, M., & Kolch, W. (2004) · Science · doi:10.1126/science.1103233 · Cited by 317
Chen, J., Fujii, K., Zhang, L., Roberts, T., & Fu, H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141224398 · Cited by 316
Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene
Mikula, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1952 · Cited by 311
MEK kinase activity is not necessary for Raf-1 function
Huser, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1940 · Cited by 310
BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
Dong, J., Phelps, R. G., Qiao, R., Yao, S., Benard, O., Ronai, Z. A., & Aaronson, S. A. (2003) · PubMed · Cited by 310
Turner, K., Moore, J. W., Jones, A., Taylor, C., Cuthbert-Heavens, D., Cheng, H., Leek, R., Gatter, K. C., Maxwell, P. H., Ratcliffe, P. J., et al. (2002) · PubMed · Cited by 303
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
Chan, S. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602162 · Cited by 301
Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.
Oka, H., Chatani, Y., Hoshino, R., Ogawa, O., Kakehi, Y., Terachi, T., Okada, Y., Kawaichi, M., Kohno, M., & Yoshida, O. (1995) · PubMed · Cited by 299
Rahmani, M., Davis, E. M., Bauer, C., Dent, P., & Grant, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506551200 · Cited by 288
Yu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., & Adjei, A. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208841 · Cited by 277
Self-citationSalvatore, G., Giannini, R., Faviana, P., Caleo, A., Migliaccio, I., Fagin, J. A., Nikiforov, Y. E., Troncone, G., Palombini, L., Basolo, F., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032221 · Cited by 259
Analysis of the transcriptional program induced by Raf in epithelial cells
Schulze, A., Lehmann, K., Jefferies, H. B. J., McMahon, M., & Downward, J. (2001) · Genes & Development · doi:10.1101/gad.191101 · Cited by 259
Positive and negative regulation of Raf kinase activity and function by phosphorylation
Chong, H. (2001) · The EMBO Journal · doi:10.1093/emboj/20.14.3716 · Cited by 255
Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation
Abraham, D., Podar, K., Pacher, M., Kubicek, M., Welzel, N., Hemmings, B. A., Dilworth, S. M., Mischak, H., Kolch, W., & Baccarini, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003259200 · Cited by 219
USING TUMOR MARKERS TO PREDICT THE SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
KIM, H. L., SELIGSON, D., LIU, X., JANZEN, N., BUI, M. H. T., YU, H., SHI, T., BELLDEGRUN, A. S., HORVATH, S., & FIGLIN, R. A. (2005) · Journal of Urology · doi:10.1097/01.ju.0000154351.37249.f0 · Cited by 216
Raf-1 regulates Rho signaling and cell migration
Ehrenreiter, K., Piazzolla, D., Velamoor, V., Sobczak, I., Small, J. V., Takeda, J., Leung, T., & Baccarini, M. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409162 · Cited by 207
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91005-6 · Cited by 204
Barnes, D. J., Palaiologou, D., Panousopoulou, E., Schultheis, B., Yong, A. S. M., Wong, A., Pattacini, L., Goldman, J. M., & Melo, J. V. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0076 · Cited by 200
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations
Chudnovsky, Y., Adams, A. E., Robbins, P. B., Lin, Q., & Khavari, P. A. (2005) · Nature Genetics · doi:10.1038/ng1586 · Cited by 198
Slaton, J. W., Inoue, K., Perrotte, P., El-Naggar, A. K., Swanson, D. A., Fidler, I. J., & Dinney, C. P. N. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64016-3 · Cited by 195
Signaling pathways in Ras-mediated tumorigenicity and metastasis
Webb, C. P., Van Aelst, L., Wigler, M. H., & Vande Woude, G. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8773 · Cited by 192
Alexia, C., Fallot, G., Lasfer, M., Schweizer-Groyer, G., & Groyer, A. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.029 · Cited by 191
Gunaratnam, L., Morley, M., Franovic, A., de Paulsen, N., Mekhail, K., Parolin, D. A. E., Nakamura, E., Lorimer, I. A. J., & Lee, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305502200 · Cited by 188
Pak-1 Expression Increases with Progression of Colorectal Carcinomas to Metastasis
Carter, J. H., Douglass, L. E., Deddens, J. A., Colligan, B. M., Bhatt, T. R., Pemberton, J. O., Konicek, S., Hom, J., Marshall, M., & Graff, J. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0210 · Cited by 185
Bos, R., Van Diest, P. J., De Jong, J. S., Van Der Groep, P., Van Der Valk, P., & Van Der Wall, E. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02045.x · Cited by 180
Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation
Baumann, B., Weber, C. K., Troppmair, J., Whiteside, S., Israel, A., Rapp, U. R., & Wirth, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.080583397 · Cited by 177
Fleming, J. B., Shen, G.-L., Holloway, S. E., Davis, M., & Brekken, R. A. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0206 · Cited by 176
Gray‐Schopfer, V. C., Dias, S. D. R., & Marais, R. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-5865-1 · Cited by 160
Activation of Raf by ionizing radiation
Kasid, U. N., Suy, S., Dent, P., Ray, S., Whiteside, T. L., & Sturgill, T. W. (1996) · Nature · doi:10.1038/382813a0 · Cited by 153
Jin, S., Zhuo, Y., Guo, W., & Field, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413374200 · Cited by 147
Tomisawa, M., Tokunaga, T., Oshika, Y., Tsuchida, T., Fukushima, Y., Sato, H., Kijima, H., Yamazaki, H., Ueyama, Y., Tamaoki, N., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00278-0 · Cited by 147
Tomizawa, Y., Iijima, H., Sunaga, N., Sato, K., Takise, A., Otani, Y., Tanaka, S., Suga, T., Saito, R., Ishizuka, T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0441 · Cited by 145
Davis, J. M., Navolanic, P. M., Oppenheimer, C. W., Steelman, L. S., Hu, W., Konopleva, M. Y., Blagosklonny, M. V., & McCubrey, J. A. (2003) · PubMed · Cited by 145
Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma*1
Hwang, Y. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.02.009 · Cited by 143
Pollock, C. B., Shirasawa, S., Sasazuki, T., Kölch, W., & Dhillon, A. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1911 · Cited by 131
Molecular Mechanisms Involved in Macrophage Survival, Proliferation, Activation or Apoptosis
Xaus, J., Comalada, M., Valledor, A. F., Cardó, M., Herrero, C., Soler, C., Lloberas, J., & Celada, A. (2001) · Immunobiology · doi:10.1078/0171-2985-00091 · Cited by 129
Amplification of oncogenes revisited: from expression profiling to clinical application
Savelyeva, L., & Schwab, M. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00472-4 · Cited by 128
Vasko, V. V., Hu, S., Wu, G., Xing, J. C., Ларін, О. С., Savchenko, V., Trink, B., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2353 · Cited by 121
Tolcher, A. W., Reyno, L. M., Venner, P. M., Ernst, S., Moore, M. J., Geary, R. S., Chi, K., Hall, S. R. R., Walsh, W., Dorr, A., et al. (2002) · PubMed · Cited by 119
Walker, F., Kato, A., Góñez, L. J., Hibbs, M. L., Pouliot, N., Levitzki, A., & Burgess, A. W. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.7192 · Cited by 119
Salomoni, P., Wasik, M. A., Riedel, R. F., Reiss, K., Choi, J. K., Skórski, T., & Calabretta, B. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.1995 · Cited by 116
Sananbenesi, F. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1188 · Cited by 114
Grana, T. M., Rusyn, E. V., Zhou, H., Sartor, C. I., & Cox, A. D. (2002) · PubMed · Cited by 114
Khatib, A., Fallavollita, L., Wancewicz, E. V., Monia, B. P., & Brodt, P. (2002) · PubMed · Cited by 114
Akslen, L. A., Angelini, S., Straume, O., Bachmann, I. M., Molven, A., Hemminki, K., & Kumar, R. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23788.x · Cited by 111
Uhlman, D. L., Nguyen, P., Manivel, J. C., Zhang, G., Hagen, K., Fraley, E. E., Aeppli, D. M., & Niehans, G. A. (1995) · PubMed · Cited by 111
Yuspa, S. H., Kilkenny, A., Stanley, J. R., & Lichti, U. F. (1985) · Nature · doi:10.1038/314459a0 · Cited by 104
Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L., & Neckers, K. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.2.277 · Cited by 104
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines
Tanami, H., Imoto, I., Hirasawa, A., Yuki, Y., Sonoda, I., Inoue, J., Yasui, K., Misawa-Furihata, A., Kawakami, Y., & Inazawa, J. (2004) · Oncogene · doi:10.1038/sj.onc.1208152 · Cited by 97
Analysis of VEGF-responsive genes involved in the activation of endothelial cells.
Wary, K. K., Thakker, G. D., Humtsoe, J. O., & Yang, J. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-25 · Cited by 97
Cripps, M. C., Figueredo, A. T., Oza, A. M., Taylor, M. J., Fields, A. L. A., Holmlund, J. T., McIntosh, L., Geary, R. S., & Eisenhauer, E. A. (2002) · PubMed · Cited by 96
Yoshida, D., Kim, K., Noha, M., & Teramoto, A. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-3279-0 · Cited by 95
The role of Raf kinases in malignant transformation
Kölch, W., Kotwaliwale, A., Vass, K., & Janosch, P. (2002) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399402004386 · Cited by 91
Rudin, C. M., Marshall, J. L., Huang, C. H., Kindler, H. L., Zhang, C., Kumar, D., Gokhale, P. C., Steinberg, J., Wanaski, S., Kasid, U. N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0642 · Cited by 90
LoRusso, P. M., Krishnamurthi, S., Rinehart, J. J., Nabell, L., Croghan, G. A., Varterasian, M. L., Sadis, S., Menon, S. S., Leopold, J., & Meyer, M. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3011 · Cited by 89
The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein
Keller, E. T., Fu, Z., & Brennan, M. M. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20169 · Cited by 87
Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas
Hemmerlein, B., Kugler, A., Özisik, R., Ringert, R.-H., Radzun, H., & Thelen, P. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280100464 · Cited by 86
Yoon, J., Werneburg, N. W., Higuchi, H., Canbay, A. E., Kaufmann, S. H., Akgul, C., Edwards, S. W., & Gores, G. J. (2002) · PubMed · Cited by 83
Igarashi, H., Esumi, M., Ishida, H., & Okada, K. (2002) · Cancer · doi:10.1002/cncr.10635 · Cited by 81
Pancreatic Cancer Cell Radiation Survival and Prenyltransferase Inhibition: The Role of K-Ras
Brunner, T. B., Cengel, K. A., Hahn, S. M., Wu, J., Fraker, D. L., McKenna, W. G., & Bernhard, E. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0158 · Cited by 79
Pirollo, K. F., Hao, Z., Rait, A. S., Ho, C. W., & Chang, E. H. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.5922 · Cited by 75
Oza, A. M., Elit, L. M., Swenerton, K., Faught, W., Ghatage, P., Carey, M., McIntosh, L., Dorr, A., Holmlund, J., & Eisenhauer, E. A. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(02)00144-0 · Cited by 75
Negative regulation of mitochondrial VDAC channels by C-Raf kinase
Mellay, V. L., Troppmair, J., Benz, R., & Rapp, U. R. (2002) · BMC Cell Biology · doi:10.1186/1471-2121-3-14 · Cited by 65
Clinical significance of BRAF mutations in metastatic melanoma
Chang, D. Z., Panageas, K. S., Osman, I., Polsky, D., BUSAM, K. J., & Chapman, P. B. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-46 · Cited by 65
Négrier, S., Maral, J., Drevon, M., et al. (2000) · PubMed · Cited by 61
Edin, M. L., & Juliano, R. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4466-4475.2005 · Cited by 59
Raf‐1 expression may influence progression to androgen insensitive prostate cancer
Mukherjee, R., Bartlett, J. M. S., Krishna, N. S., Underwood, M. A., & Edwards, J. (2005) · The Prostate · doi:10.1002/pros.20211 · Cited by 57
Goodman, G. E. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00074-8 · Cited by 54
Mammalian Sterile 20–Like Kinases in Tumor Suppression: An Emerging Pathway
O’Neill, E. E., Matallanas, D., & Kölch, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1453 · Cited by 54
RAF antisense oligonucleotide as a tumor radiosensitizer
Kasid, U. N., & Dritschilo, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206700 · Cited by 50
Tsuchiya, N., Sato, K., Akao, T., Kakinuma, H., Sasaki, R., Shimoda, N., Satoh, S., Habuchi, T., Ogawa, O., & Kato, T. (2001) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.195.101 · Cited by 46
Halaschek-Wiener, J., Wacheck, V., Kloog, Y., & Jansen, B. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.04.003 · Cited by 45
Eppstein, D. A., Marsh, Y. V., Schryver, B. B., & Bertics, P. J. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041410224 · Cited by 45
Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter
Kim, S., Lee, S., Kwak, N.-H., Kang, C., & Chung, B. (1996) · Cancer Letters · doi:10.1016/0304-3835(95)04023-4 · Cited by 39
Belly, R. T., Rosenblatt, J. D., Steinmann, M., Toner, J., Sun, J., Shehadi, J. A., Peacock, J. L., Raubertas, R. F., Jani, N. D., & Ryan, C. (2001) · Clinical Colorectal Cancer · doi:10.3816/ccc.2001.n.011 · Cited by 38
Hamden, K. E., Whitman, A. G., Ford, P. W., Shelton, J. G., McCubrey, J. A., & Akula, S. M. (2004) · Leukemia · doi:10.1038/sj.leu.2403532 · Cited by 37
Antisense Oligonucleotide Targeting of Raf-1
Mullen, P., McPhillips, F., MacLeod, K. G., Monia, B. P., Smyth, J. F., & Langdon, S. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0154 · Cited by 30
Imatinib mesylate—gold standards and silver linings
Peggs, K. S. (2004) · Clinical and Experimental Medicine · doi:10.1007/s10238-004-0032-5 · Cited by 17
Prevention of Lung Cancer: The New Millennium
Kim, E. S., Hong, W. K., & Khuri, F. R. (2000) · Chest Surgery Clinics of North America · doi:10.1016/s1052-3359(25)00535-6 · Cited by 16
Larsson, L. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4279-5 · Cited by 11
Cited by
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Chen, M. H., Kerkelä, R., & Force, T. (2008) · Circulation · doi:10.1161/circulationaha.108.776831 · Cited by 379
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370
Analysis of MiR-195 and MiR-497 Expression, Regulation and Role in Breast Cancer
Li, D., Zhao, Y., Liu, C., Chen, X., Qi, Y., Jiang, Y., Zou, C., Zhang, X., Liu, S., Wang, X., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1800 · Cited by 317
Metadata
- Authors
- GOLLOB, J., WILHELM, S., CARTER, C., & KELLEY, S.
- Venue
- Seminars in Oncology
- Publisher
- Elsevier BV
- Published
- 2006-08
- Volume
- 33
- Issue
- 4
- Pages
- 392-406
- ISSN
- 0093-7754 (ISSN-L)
- OpenAlex
- W2139213909
- Cited by
- 360
- References
- 126
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.